Aptevo Therapeutics shares are trading higher after the company and Alligator Bioscience announced interim data from the Phase 1 trial of ALG.APV-527 monotherapy, showing 60% of evaluable patients achieved stable disease in a solid tumor study.
Portfolio Pulse from Benzinga Newsdesk
Aptevo Therapeutics shares rose following positive interim data from a Phase 1 trial of ALG.APV-527 monotherapy, with 60% of patients achieving stable disease in a solid tumor study.
September 16, 2024 | 12:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aptevo Therapeutics shares increased due to positive interim results from a Phase 1 trial of ALG.APV-527, with 60% of patients achieving stable disease.
The positive interim data from the Phase 1 trial of ALG.APV-527 is a significant milestone for Aptevo Therapeutics, indicating potential efficacy in treating solid tumors. This news likely boosts investor confidence, leading to a rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100